Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,354.40 +121.18 0.80%
S&P 500 1,667.47 +17.00 1.03%
Nasdaq 3,498.97 +33.72 0.97%
Ticker Volume Price Price Delta
STOXX 50 2,817.99 +11.29 0.40%
FTSE 100 6,723.06 +35.26 0.53%
DAX 8,398.00 +28.13 0.34%
Ticker Volume Price Price Delta
Nikkei 15,138.10 +100.88 0.67%
Hang Seng 23,082.70 +38.44 0.17%
S&P/ASX 200 5,180.77 +15.11 0.29%
  • Fund Type: Closed-End Fund
  • Objective: Sector Fund-Health & Biotech
  • Asset Class: Equity
  • Geographic Focus: U.S.

H&Q Life Sciences Investors

+ Add to Watchlist

HQL:US

18.8600 USD 0.6700 3.43%

As of 20:04:03 ET on 05/17/2013.

Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Snapshot for H&Q Life Sciences Investors (HQL)

Open: 19.5700 High - Low: 19.6700 - 18.5700 Primary Exchange: New York
Volume: 126,803 52-Week Range: 12.8600 - 21.0000 Beta vs NBI: 0.7901

ETF Chart for HQL

No chart data available.
  • HQL:US 18.8600
  • 1D
  • 1M
  • 1Y
18.8600
Interactive HQL Chart

Previous Close

Fund Profile & Information for HQL

H&Q Life Sciences Investors is a diversified, closed-end management investment company incorporated in the USA. The Fund's objective is long-term capital appreciation. The Fund invests mainly in securities of life sciences companies. The Fund invests primarily in securities of public and private companies that are believed to have significant potential for above-average growth.

Inception Date: 1992-05-08 Telephone: 1-617-772-8500
Managers: DANIEL R OMSTEAD
Web Site: www.teklacap.com

Fundamentals for HQL

NAV (on 2013-05-17) 18.6300
Assets (M) (on 2013-05-17) 274.0941
Shares out (M) 14.71
Market Cap (M) 277.44
% Premium 1.23
Average 52-Week % Premium -1.5304
Fund Leveraged N

Dividends for HQL

Dividend Type Income
Dividend Frequency Quarter
Last Dividend Net (on 2013-05-23) 0.3400
Dividend Yield (ttm) 6.36%

Performance for HQL

1-Month +5.36% 1-Year +42.68%
3-Month +21.64% 3-Year +35.85%
Year To Date +32.54% 5-Year +18.05%
Expense Ratio 1.72

Top Fund Holdings for HQL

Filing Date: 03/31/2012
Name Position Value % of Total
Teva Pharmaceutical Industries 209,841 9,455,436 4.546%
Celgene Corp 107,767 8,354,098 4.017%
Alexion Pharmaceuticals Inc 87,744 8,147,908 3.918%
Gilead Sciences Inc 326,302 7,969,926 3.832%
Akorn Inc 580,157 6,787,837 3.264%
Vertex Pharmaceuticals Inc 161,202 6,610,894 3.179%
Mylan Inc/PA 279,254 6,548,506 3.149%
Perrigo Co 60,055 6,204,282 2.983%
Regeneron Pharmaceuticals Inc 48,995 5,713,797 2.747%
Illumina Inc 100,700 5,297,827 2.547%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Financial Commentaries

Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil